Your browser doesn't support javascript.
loading
Expression of Hematopoietic Stem and Endothelial Cell Markers in Canine Hemangiosarcoma.
Kakiuchi-Kiyota, Satoko; Obert, Leslie A; Crowell, Danielle M; Xia, Shuhua; Roy, Marc D; Coskran, Timothy M; Kreeger, John M; Crabbs, Torrie A; Cohen, Samuel M; Cattley, Russell C; Cook, Jon C.
Afiliación
  • Kakiuchi-Kiyota S; Drug Safety Research & Development, Pfizer Inc., Groton, CT, USA.
  • Obert LA; Drug Safety Research & Development, Pfizer Inc., Groton, CT, USA.
  • Crowell DM; Drug Safety Research & Development, Pfizer Inc., Groton, CT, USA.
  • Xia S; Drug Safety Research & Development, Pfizer Inc., Groton, CT, USA.
  • Roy MD; Drug Safety Research & Development, Pfizer Inc., Groton, CT, USA.
  • Coskran TM; Drug Safety Research & Development, Pfizer Inc., Groton, CT, USA.
  • Kreeger JM; Drug Safety Research & Development, Pfizer Inc., Groton, CT, USA.
  • Crabbs TA; Experimental Pathology Laboratories, Inc., Research Triangle Park, NC, USA.
  • Cohen SM; Department of Pathology and Microbiology, University of Nebraska Medical Center, NE, USA.
  • Cattley RC; Department of Pathobiology, College of Veterinary Medicine, Auburn University, AL, USA. Kakiuchi-Kiyota is now with Safety Assessment, Genentech Inc., South San Francisco, CA, USA; Obert is now with Translational Medicine & Comparative Pathology, GlaxoSmithKline, Collegeville, PA, USA; Roy is no
  • Cook JC; Drug Safety Research & Development, Pfizer Inc., Groton, CT, USA.
Toxicol Pathol ; 48(3): 481-493, 2020 04.
Article en En | MEDLINE | ID: mdl-31918642
ABSTRACT
Several chemicals and pharmaceuticals increase the incidence of hemangiosarcomas (HSAs) in mice, but the relevance to humans is uncertain. Recently, canine HSAs were identified as a powerful tool for investigating the pathogenesis of human HSAs. To characterize the cellular phenotype of canine HSAs, we evaluated immunoreactivity and/or messenger RNA (mRNA) expression of markers for hematopoietic stem cells (HSCs), endothelial cells (ECs), a tumor suppressor protein, and a myeloid marker in canine HSAs. Neoplastic canine cells expressed EC markers and a myeloid marker, but expressed HSC markers less consistently. The canine tumor expression results were then compared to previously published immunoreactivity results for these markers in human and mouse HSAs. There are 2 noteworthy differences across species (1) most human HSAs had HSC marker expression, indicating that they were comprised of tumor cells that were less differentiated than those in canine and mouse tumors; and (2) human and canine HSAs expressed a late-stage EC maturation marker, whereas mouse HSAs were negative, suggesting that human and canine tumors may retain greater differentiation potential than mouse tumors. These results indicate that HSA development is variable across species and that caution is necessary when discussing translation of carcinogenic risk from animal models to humans.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Enfermedades de los Perros / Hemangiosarcoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Toxicol Pathol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Enfermedades de los Perros / Hemangiosarcoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Toxicol Pathol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos